We evaluated the ability of a simple scoring system for prediction of outcome soon after subarachnoid hemorrhage(SAH). The scoring system was calculated on the basis of the distribution of blood seen on the CT scan and patients' neurological grade on admission. Two points each were scored for interhemispheric, intraventricular, basal and intracerebral hemorrhage. We excluded hemorrhage in the Sylvian cistern from the calculation of the scoring system. Patients in neurological grade 1-3 scored -1, grade 4 scored 0, grades 5 & 6 scored +5. The CT score and grade score were summated to give the overall score. Patients were placed in 3 risk groups, low risk group in score of -1, medium risk group in score of 0-2, and high risk group in score above 3. The scoring system was applied prospectively to 134 patients who were admitted to our hospital from January 1995 to December 1996. The overall mortality rate was 32.1% within 3 months after onset of SAH. There was a close relationship between the patients' scores and their outcomes. Over 90% of low risk patients experienced a full and good recovery from the SAH compared to 30% of high risk patients. Less than 5% of low risk patients were died, whereas 56% of high risk group died. Thus a low risk patient has a better outcome than a high risk patient(p<0.001). The classification into risk groups has predictive value independent of angiographic finding, hypertension and vasospasm.
Cerebral Hemorrhage ; Classification ; Hemorrhage ; Humans ; Hypertension ; Mortality ; Prospective Studies ; Tomography, X-Ray Computed

PURPOSE: Recently in light of the development in immunology, interferon- e and inter- leukin-2 or combination therapy with anticancer drugs have been performed. This study aims to verify and compare the efficacy of therapies using interferon- a alone, interferon- a plus vinblastine, and interferon- a plus interleukin-2 plus 5-fluorouracil (5-FU) plus 13-cis retinoic acid (13cRA) in patients with advanced renal cell carcinoma. MATERIALS AND METHODS: A total of 29 patients were randomly assigned to receive treatment with either interferon- a alone or interferon- a plus vinblastine or interferon- a plus interleukin-2 plus 5-FU plus 13cRA from December 1989 to May 1998. The most frequent metastatic sites were the lung, lymph nodes, bone, liver, and brain. We studied the response rates, survival period, and complications of each regimen. RESULTS: Responses were achieved in 1 out of 1~5 patients (6.73?o) on interferon- a alone (partial responses lasting 13 months), 1 out of 9 patients (11.1%) on interferon- e plus vinblastine (partial responses lasting 25 months) and 1 out of 5 patients (20.0%) on interferon-a plus IL-2 plus 5-FU plus 13cRA regimen (partial responses lasting 14 months). The median durations of survival were 18, 33, and 23 months respectively. The overall response rate was 10.3% and overall median duration of survival was 19 months. The most common side effects were flu-like symptom such as fever, chills (93.1%), skin symptom such as erythema, pruritus (31.0%), G-I symptom such as nausea, vomiting (17.2%), netropenia (10.3%), abnormal LFT (10.3%), and thrombocytopenia (3.4%). CONCLUSIONS: This study confirms the manageability and tolerability of several regimen used. There is no significant differences in response rates and survival duration among the regimens used in this study. The effective immunotherapy in patients with metastatic RCC should be evaluated by further studies of larger patients groups even though a minority of patients responded.
Allergy and Immunology ; Brain ; Carcinoma, Renal Cell* ; Chills ; Erythema ; Fever ; Fluorouracil ; Humans ; Immunotherapy* ; Interferon-alpha ; Interferons* ; Interleukin-2 ; Liver ; Lung ; Lymph Nodes ; Nausea ; Pruritus ; Skin ; Survival Rate ; Thrombocytopenia ; Tretinoin ; Vinblastine ; Vomiting

No abstract available.
Adult* ; Helicobacter pylori* ; Helicobacter* ; Humans ; Risk Factors*

Down syndrome is the most, well known autosomal trisomy and e large number of abnormal skin features have been reported to occur in patients with Down syndromir. including syringoma. Syringomas occur with increased frequency in patients with Down syringoma, usually limited to the region around the eyes. but few cases of eruptive syringoma with Down syndrome have been reported. We reported the case of familial eruptive syringoma in a 13 years old patient with Down syndrome.
Adolescent ; Down Syndrome* ; Humans ; Livedo Reticularis ; Skin ; Syringoma* ; Trisomy

No abstract available.
Axis, Cervical Vertebra* ; Estradiol* ; Testosterone*

No abstract available.
Stomach Neoplasms* ; Stomach*

No abstract available.
Adrenocorticotropic Hormone* ; Animals ; Plasma* ; Rats*

No abstract available.
Choledocholithiasis*

Skin necrosis is a rare complication of heparin administration that is usually localized to injection sites. We report a case of skin necrosis that was caused by minidose intraarterial infusion of porcine heparin which had been used in a touch to prevent coagulation in percutaneous intraarterial cannula. The skin necrosis appeared 35 days after starting heparin use.
Catheters ; Heparin* ; Infusions, Intra-Arterial ; Necrosis* ; Skin

No abstract available.
Animals ; Embryonic Structures* ; Freezing* ; Mice* ; Sucrose*